Skip to main content

Table 2 Multivariate analysis of the impact of demographic, laboratory, and molecular parameters on overall survival in the entire study group

From: Clinical features of De Novo acute myeloid leukemia with concurrent DNMT3A, FLT3 and NPM1 mutations

 

P-value

HR

95% CI

Lower

Upper

Age

0.019

1.032

1.005

1.060

Sex

0.688

0.881

0.476

1.631

FLT3 mutation

0.222

1.521

0.775

2.985

NPM1 mutation

0.476

1.306

0.627

2.720

DNMT3A mutation

0.026

2.552

1.120

5.816

IDH 1 mutation

0.002

0.223

0.085

0.588

IDH 2 mutation†

0.134

0.407

0.125

1.320

Poor risk cytogenetics*

0.018

4.584

1.297

16.199

CN-AML

0.358

1.596

0.589

4.328

BM blast percentage

0.487

0.995

0.981

1.009

PB blast percentage

0.692

1.002

0.992

1.012

Hemoglobin

0.864

0.984

0.816

1.186

White blood count

0.640

1.002

0.995

1.008

  1. †Include 17 cases with IDH2R140 and 2 with IDH2R172[25].
  2. *Poor-risk vs intermediate and better risk categories per National Comprehensive Cancer Network guidelines (version 2.2013) [26].
  3. Abbreviations: HR hazards ratio, CI confidence interval, BM bone marrow, PB peripheral blood, CN-AML cytogenetically normal (diploid) acute myeloid leukemia.
  4. Bold font indicates parameters with significant impact on overall survival.
Back to article page

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us